Compare Ascendis Pharma A/S (ASND) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Moody's Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Moody's Corporation trades at $480.01 (market cap $85.12B). The key difference: Moody's Corporation is far larger — about 4.8× Ascendis Pharma A/S's market cap, and Moody's Corporation pays a 0.85% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MCO | |
|---|---|---|
Market Cap | $17.74B | $85.12B |
Sector | Health | Financials |
52-Week High | $277.18 | $539.61 |
52-Week Low | $163.32 | $412.23 |
Enterprise Value | $18.11B | $90.92B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MCO trades at $487.28, up 0.05% on the day, with a bullish technical signal supported by moving averages and strong fundamentals. The company reported Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 31.69% net income margin. Recent news highlights Moody's AI initiatives, including new AI skills and integrations, positioning for growth in credit analytics. The stock is near its 52-week high, with support at $481 and resistance at $490.
Outlook remains positive with a consensus price target of $539.40, implying 11% upside, driven by earnings momentum and AI adoption. Risks include high valuation multiples (P/E 34.96) and dependence on debt issuance cycles. Institutional sentiment is bullish with 56% buy ratings, but overbought RSI levels suggest near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
